Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Materials

Warner Babcock Forms Drug Technology Firm

by Michael McCoy
October 31, 2011 | A version of this story appeared in Volume 89, Issue 44

The Warner Babcock Institute for Green Chemistry has joined with the venture capital firm Elm Street Ventures to form Occam Sciences, a New Haven, Conn.-based company that will develop new forms of existing drugs with optimized bioavailability. Occam is based on WBI’s noncovalent derivatization technology, which alters selected physical properties in target drugs. WBI CEO Joe Pont says the technology has already been successfully commercialized in other industries.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.